A diagnostic method according to an embodiment of the present disclosure for determining prognosis including recurrence and/or death, which commonly occurs after acute coronary syndrome. A method of determining long-term prognosis of acute coronary syndrome according to an embodiment of the present disclosure is capable of determining the risk of incidence of major adverse cardiac events including recurrence and/or death after acute coronary syndrome in acute coronary syndrome patients suffering from depression by analyzing the extent of NR3C1 methylation.

A composition of a bilimbin stock and a method of preparation are provided. In one aspect of the invention, the composition includes a base solution. The composition further includes a carbonate salt. Additionally, the composition includes bilimbin. Furthermore, the composition includes human serum albumin

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently —OH, —OP(O)(OH)2 or —P(O)(OH)2, with the proviso that at least two R are independently selected from —P(O)(OH)2 and —OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

Reagents are disclosed for use with potentiometric magnesium ion selective electrodes, along with kits containing same as well as methods of use thereof. Before explaining at least one embodiment of the inventive concept(s) in detail by way of exemplary drawings, experimentation, results, and laboratory procedures, it is to be understood that the inventive concept(s) is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings, experimentation and/or results.

Methods of identifying a compound, such as a test compound, and applications thereof are provided. For example, methods of identifying a compound that preferentially affects, increases, or decreases a level of association of a macromolecule with one or more target condensates or methods of identifying a compound that preferentially causes a macromolecule to associate or disassociate with one or more target condensates are provided. Additionally, methods of designing and/or identifying and/or making a compound, or portion thereof, with a desired characteristic are provided.

Fluorescent viral particles, including viral particles and a fluorescent dye conjugated to the viral particles, are used for viral contaminant removal testing as part of viral clearance evaluation for biological medical product preparation processes. The conjugated fluorescent dye adds only marginally to viral particle size, but provides versatility both for rapid screening of alternative viral removal approaches during process development and for final process validation, as the fluorescent viral particles have fluorescent activity throughout the viral clearance evaluation process, permitting rapid and consistent quantification of initial test solutions, resulting purified solutions, and intermediate solutions of interest at any point during processing under evaluation.

A compound and a method of detecting CLN3 are provided. The compound includes a heavy isotope labeled CLN3 proteotypic peptide. The method includes i) selecting a CLN3 proteotypic peptide that exhibits linear behavior in the mass spectrometer; ii) generating a stable isotope labeled standard; iii) spiking known amounts of the stable isotope labeled standard into a sample to form a spiked sample; iv) determining retention times and establishing calibration curves using the spiked sample; and v) detecting unlabeled selected CLN3 proteins in the sample.

A microdevice includes a plurality of calibration curve liquids, a plurality of first microchannels respectively filled with the plurality of calibration curve liquids, at least one second microchannel filled with a measurement target liquid, and a sealing member that closes openings of the first microchannels to seal the calibration curve liquids. Each of the calibration curve liquids includes a measurement target substance of a predetermined concentration, the predetermined concentration in each of the plurality of calibration curve liquid being mutually different, an antibody that specifically binds to the measurement target substance, and a fluorescent-labeling derivative that fluorescently labels the measurement target substance and competes with the measurement target substance to specifically bind to the antibody. The measurement target liquid includes an unknown concentration of the measurement target substance, the antibody, and the fluorescent-labeling derivative.

Anti-SARS-CoV-2 fusion peptides are provided. The anti-SARS-CoV-2 fusion peptides include peptide sequences corresponding to the sequence of the SARS-CoV-2 fusion complex heptad repeat domain HR2 and having at least one artificial mutation. The anti-SARS-CoV-2 fusion peptides may be 39-mers, such as peptides #121 (SEQ ID NO: 2) and #125 (SEQ ID NO: 5). These peptides may competitively bind to SARS-CoV-2 and prevent either membrane mediated SARS-CoV-2 fusion, endocytosis-mediated viral entry, or both. The anti-SARS-CoV-2 fusion peptides may be administered to a subject in need thereof to inhibit or prevent SARS-CoV-2 cellular entry.

Provided herein are methods of treating cancer with a TPH1 inhibitor. In certain embodiments, methods are provided which display remarkable efficacy and bioavailability for the treatment of certain tumors, for example, a neuroendocrine tumor in a human patient. In certain embodiments, the methods comprising treating the patient with telotristat, a telotristat prodrug, or a pharmaceutically acceptable salt thereof, which can be administered either alone or in combination with other anticancer or antidiarrheal agents.